NewsBenzingaEdesa Biotech、尋常性白斑におけるEB06の第2相臨床試験に関する治験薬（IND）申請についてFDAの承認を取得 Edesa Biotech、尋常性白斑におけるEB06の第2相臨床試験に関する治験薬（IND）申請についてFDAの承認を取得 Benzinga 2026.10.15 13:16 (GMT+0) Open on Benzinga Other news Stocks Supported by a Rebound in Chipmakers and AI-Infrastructure Companies Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know. 3 Token Unlocks to Watch in the Fourth Week of October 2026 Rocket Lab's Biggest Technological Advantage Is Fast Becoming Its Biggest Problem Why Is IREN Stock Surging Monday? Venture Global Stock Just Secured a Data Center Win. How to Play It Here.
Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know.
